AbbVie (ABBV)
(Delayed Data from NYSE)
$167.29 USD
-0.51 (-0.30%)
Updated Apr 25, 2024 04:00 PM ET
After-Market: $166.50 -0.79 (-0.47%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth D Momentum C VGM
Price, Consensus and EPS Surprise
ABBV 167.29 -0.51(-0.30%)
Will ABBV be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for ABBV based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ABBV
Zacks Industry Outlook Highlights Eli Lilly, Novo Nordisk, Merck and AbbVie
Will Healthcare ETFs Lose Momentum as Q1 Earnings Unfold?
ABBV: What are Zacks experts saying now?
Zacks Private Portfolio Services
4 Large Drug Stocks to Hold on to Amid Industry Challenges
What's in Store for These 5 Pharma Bigwigs in Q1 Earnings?
Is Invesco Pharmaceuticals ETF (PJP) a Strong ETF Right Now?
Other News for ABBV
GLOBAL BRIEFING: Yen slumps to new multi-decade low as BoJ stands pat
NEW YORK MARKET CLOSE: Stocks ebb on stagflation fears as growth slows
Notable companies reporting before tomorrow's open
Alucio™ Introduces Next Iteration of Product Advisory Board
AbbVie reports positive results from Rinvoq versus Dupixent study